JP2022526267A5 - - Google Patents

Info

Publication number
JP2022526267A5
JP2022526267A5 JP2021555448A JP2021555448A JP2022526267A5 JP 2022526267 A5 JP2022526267 A5 JP 2022526267A5 JP 2021555448 A JP2021555448 A JP 2021555448A JP 2021555448 A JP2021555448 A JP 2021555448A JP 2022526267 A5 JP2022526267 A5 JP 2022526267A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
modified oligonucleotide
composition according
pbs
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021555448A
Other languages
English (en)
Japanese (ja)
Other versions
JP7564817B2 (ja
JP2022526267A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/022680 external-priority patent/WO2020190740A1/en
Publication of JP2022526267A publication Critical patent/JP2022526267A/ja
Publication of JP2022526267A5 publication Critical patent/JP2022526267A5/ja
Priority to JP2024168231A priority Critical patent/JP2025000805A/ja
Application granted granted Critical
Publication of JP7564817B2 publication Critical patent/JP7564817B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021555448A 2019-03-15 2020-03-13 ｋｃｎｔ１発現を低減するための化合物及び方法 Active JP7564817B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024168231A JP2025000805A (ja) 2019-03-15 2024-09-27 ｋｃｎｔ１発現を低減するための化合物及び方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962819344P 2019-03-15 2019-03-15
US62/819,344 2019-03-15
US201962884501P 2019-08-08 2019-08-08
US62/884,501 2019-08-08
PCT/US2020/022680 WO2020190740A1 (en) 2019-03-15 2020-03-13 Compounds and methods for reducing kcnt1 expression

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024168231A Division JP2025000805A (ja) 2019-03-15 2024-09-27 ｋｃｎｔ１発現を低減するための化合物及び方法

Publications (3)

Publication Number Publication Date
JP2022526267A JP2022526267A (ja) 2022-05-24
JP2022526267A5 true JP2022526267A5 (https=) 2023-08-24
JP7564817B2 JP7564817B2 (ja) 2024-10-09

Family

ID=72520445

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021555448A Active JP7564817B2 (ja) 2019-03-15 2020-03-13 ｋｃｎｔ１発現を低減するための化合物及び方法
JP2024168231A Pending JP2025000805A (ja) 2019-03-15 2024-09-27 ｋｃｎｔ１発現を低減するための化合物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024168231A Pending JP2025000805A (ja) 2019-03-15 2024-09-27 ｋｃｎｔ１発現を低減するための化合物及び方法

Country Status (19)

Country Link
US (2) US20220177893A1 (https=)
EP (1) EP3938514A4 (https=)
JP (2) JP7564817B2 (https=)
KR (1) KR20210141983A (https=)
CN (3) CN113661241A (https=)
AU (1) AU2020241693B2 (https=)
BR (1) BR112021015494A2 (https=)
CA (1) CA3133247A1 (https=)
CL (1) CL2021002398A1 (https=)
CO (1) CO2021013371A2 (https=)
CR (1) CR20210519A (https=)
IL (1) IL285546A (https=)
JO (1) JOP20210254A1 (https=)
MX (1) MX2021011132A (https=)
PE (1) PE20220168A1 (https=)
PH (1) PH12021552220A1 (https=)
SG (1) SG11202108625WA (https=)
TW (1) TW202102675A (https=)
WO (1) WO2020190740A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202001685TA (en) 2017-08-28 2020-03-30 Enanta Pharm Inc Hepatitis b antiviral agents
IL283190B2 (en) 2018-11-21 2025-08-01 Enanta Pharm Inc Functionalized heterocycles as antiviral agents
WO2021188414A1 (en) 2020-03-16 2021-09-23 Enanta Pharmaceuticals, Inc. Functionalized heterocyclic compounds as antiviral agents
EP4441229A1 (en) * 2021-12-01 2024-10-09 Atalanta Therapeutics, Inc. Compositions and methods for treatment of epilepsies
IL326478A (en) * 2023-08-16 2026-04-01 Servier Lab Oligonucleotides for modulation of KCNT1 expression

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050288242A1 (en) * 2001-05-18 2005-12-29 Sirna Therapeutics, Inc. RNA interference mediated inhibition of RAS gene expression using short interfering nucleic acid (siNA)
US7601501B2 (en) 2006-08-11 2009-10-13 The Scripps Research Institute Controlling osteogenesis by inhibition of osteogenic suppressors
CA2817256A1 (en) * 2010-11-12 2012-05-18 The General Hospital Corporation Polycomb-associated non-coding rnas
TW202246503A (zh) 2013-07-19 2022-12-01 美商百健Ｍａ公司 用於調節τ蛋白表現之組合物
US20200129538A1 (en) * 2017-06-13 2020-04-30 The Florey Institute Of Neuroscience And Mental Health Compositions and methods for treating conditions associated with gain-of-function mutations in kcnt1

Similar Documents

Publication Publication Date Title
JP2022526267A5 (https=)
JP2021074021A5 (https=)
JP2022501024A5 (https=)
JP2024079716A5 (https=)
JP2020022483A5 (https=)
JP4236812B2 (ja) オリゴヌクレオチド類似体
JPH05505101A (ja) オリゴヌクレオチド療法における三重らせん形成
JP2022551124A5 (https=)
ES2276515T3 (es) 2'-fluoronucleosidos.
JP2012505660A5 (https=)
JP2024535388A5 (https=)
CN100400045C (zh) 基于核酸的化合物及其使用方法
JP2007269798A (ja) Ｂ型肝炎の治療のためのβ−Ｌ−２’−デオキシ−ヌクレオシド
CN88101606A (zh) 利用双链核糖核酸与病毒抑制剂联合以治疗人病毒感染
JP2005500025A5 (https=)
JP2007503474A5 (https=)
JP2024505226A5 (https=)
Ligeour et al. Importance of topology for glycocluster binding to Pseudomonas aeruginosa and Burkholderia ambifaria bacterial lectins
JP2019534009A5 (https=)
JP2021520804A5 (https=)
AR127325A1 (es) Métodos y composiciones para el tratamiento de la enfermedad renal poliquística
JPH04226999A (ja) 抗ウイルス剤
JP2013537404A5 (https=)
US20140031309A1 (en) Beta-L-N4 Hydroxycytosine Deoxynucleosides and their use as Pharmaceutical Agents in the Prophylaxis or Therapy of Viral Diseases
JP2023524065A5 (https=)